Last reviewed · How we verify
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
This study is a randomized, double-blind, placebo-controlled, multi-center clinical study. Target population is patients with stage IV non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to compare the efficacy and safety of Camrelizumab + carboplatin/cisplatin + pemetrexed /paclitaxel / albumin paclitaxel ± SRT/WBRT with placebo + carboplatin/cisplatin + pemetrexed /paclitaxel / albumin paclitaxel ± SRT/WBRT. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
Details
| Lead sponsor | Guangdong Association of Clinical Trials |
|---|---|
| Phase | PHASE3 |
| Status | UNKNOWN |
| Enrolment | 200 |
| Start date | Fri Mar 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Non-Small-Cell Lung Cancer
Interventions
- Camrelizumab
- Placebo
- Cisplatin
- Carboplatin
- Pemetrexed
- Paclitaxel
- Albumin paclitaxel